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Collagen type VI is shown to be present in the human cornea. This finding is based on comparative peptide 
mapping relative to type VI collagen isolated from placenta and on immunoblotting using antibodies specif- 
ic for human type VI collagen. Scanning of polyacrylamide gels indicates that type VI collagen comprises 
as much as one quarter of the dry weight of the cornea. Indirect immunofluorescence shows this collagen 
to be distributed throughout he cornea1 stroma. Thus, type VI collagen must be considered a major compo- 
nent of the extracellular matrix of the human cornea. 
Collagen Extracellular matrix (Cornea, Human) 
1. INTRODUCTION 
To date, of the 11 genetically different collagen 
types described [I], 4 have been detected in the 
human cornea [2,3]. These are type I, which is the 
predominant cornea1 component, type V and small 
amounts of types III and IV. Types I, III and V are 
co-distributed in the stroma, whereas type IV is 
located in Descemet’s and Bowman’s membrane. 
Our attention has recently been focused on type 
VI collagen, a disuphide-linked protein consisting 
of a short triple helix bounded by relatively large 
globular domains [4-S]. Originally extracted from 
aorta and placenta, this collagen has since been 
detected in most other organs, including uterus, 
liver, kidney, skin, ligamenturn and skeletal muscle 
P,lOl. 
Here, we demonstrate that type VI collagen 
forms a major portion of the extracellular matrix 
This paper is dedicated to Professor C. Martius on the 
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Abb;eviations: SDS-PAGE, SDS-polyacrylamide gel 
electrophoresis; FITC, fluorescein isothiocyanate 
of the human cornea. This protein might therefore 
play an important role in the architecture of the 
cornea1 tissue. 
2. EXPERIMENTAL 
2.1 Extractions 
Normal human corneas of individuals aged be- 
tween 60 and 80 years were obtained at autopsy 
(Augenbank, Universitatsspital, Zurich). The 
frozen tissues were sliced individually with a 
microtome to give 50 km sections, washed with 
distilled water and lyophilised. After measuring 
the tissue dry weight (6-7 mg), the slices were 
swollen in 2 ml of 0.5 M acetic acid. To each cor- 
nea so prepared, 2 mg pepsin (St. Louis, MO) was 
added and digestion performed at 4°C for 24 h. 
Undigested material was removed by centrifuga- 
tion (30 000 x g, 10 min). The solubilised col- 
lagens were precipitated from the supernatant by 
adding NaCl to a final concentration of 2 M. The 
precipitate was redissolved, dialysed against 0.1 M 
acetic acid and lyophilised. The yield was deter- 
mined gravimetrically. 
The insoluble part of the cornea was washed 
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with 0.5 M acetic acid, lyophilised and resuspend- 
ed in 200~1 SDS sample buffer [l 1) containing 2% 
,!Y-mercaptoethanol. Extraction was performed at 
95°C for 10 min. 
Finally, the solubilised collagens were analysed 
on 3-10% (w/v) SDS-PAGE [1 11. Human type VI 
collagen isolated from placenta following 
established procedures [4-61 was used as a 
standard. 
2.2 CNBr cleavage 
Collagen samples were electrophoresed under 
reducing conditions on 8% polya~rylamide gels. 
After Coomassie blue staining, bands were cut out 
and subjected to CNBr cleavage in the gel slice 
[12]. Reaction was performed at 37°C for 3 h. The 
resulting peptides were separated on lo-15% 
(w/v) SDS-PAGE. 
2.3. Immunological procedures 
Antisera against type VI collagen from human 
fibroblasts were raised in rabbits and affinity- 
purified on type VI collagen from placenta [14,15]. 
The resulting antibodies recognised specifically the 
pepsinised ar(VI)- and cuz(VI)-chains, as has been 
found for similar preparations of antibodies [ 151. 
Western blotting was carried out following a 
modification of the procedure of Towbin et al. 
[ 131, in which the second antibody was replaced by 
[“2JI]iodinated protein A [8]. Bands were visualised 
by autoradiography. 
Indirect immunofluorescence using FITC- 
labelled goat anti-rabbit second antibodies (Miles, 
Naperville, IL) was performed on frozen sections 
(4 am) of human cornea as described in 1161. 
3. RESULTS AND DISCUSSION 
Pepsin digestion solubilised 5-10% of the 
original dry weight of the cornea. A subsequent ex- 
traction with SDS sample buffer yielded a further 
5--15% depending on the individual cornea. This 
variability was found to be largely due to decreased 
extractability with increasing age of the cornea. 
Analysis of the extracted collagens on SDS- 
PAGE showed under non-reducing conditions the 
typical pattern of type I collagen (fig. 1). Very little 
type V collagen could be detected. In addition, a 
blurred band migrating with an apparent 
molecular mass of 350 kDa was observed. Upon 
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Fig. 1. Comparison of pepsin-extracted collagens from 
human cornea (C) with type VI collagen from human 
palcenta (P). Proteins were separated on 3-10% SDS- 
PAGE under reducing ( + ) or non-reducing ( - ) condi- 
tions and either stained with Coomassie blue or process- 
ed for immunoblotting. Human type I collagen was used 
as standard (S). 
reduction this band disappeared and 3 distinct 
components with relative molecular masses of 53, 
49 and 44 kDa were generated. Bands of lesser in- 
tensity also appeared at about 90 and 150 kDa, 
possibly corresponding to dimeric and trimeric 
forms of the faster migrating components. An 
almost identical pattern was obtained after elec- 
trophoresis of a type VI collagen standard from 
placenta. Only a slight difference in the mobilities 
of the placental ar(VI)-chain and the correspond- 
ing corneal material was noted. 
Immunoblotting experiments using affinity- 
purified antibodies specific for the cur(VI)- and 
az(VI)-chains confirmed the presence of type VI 
collagen in human cornea. Unreduced as well as 
reduced samples showed a positive immunoreac- 
tion (fig.1). In addition to the bands in the w- 
region of type VI, the proposed dimeric and 
trimeric forms were also recognised by the 
antibodies. 
Peptide mapping provided the final proof for 
the occurrence of type VI collagen in human cor- 
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Fig.2. Analyis of CNBr fragments of the individual type 
VI collagen chains from human palcenta (P) and human 
cornea (C) on 8-15% SDS-PAGE. CNBr fragments 
from bovine type I collagen were used as standard (S). 
neas (fig.2). CNBr fragments of the individual type 
VI chains derived from placental and cornea1 
tissues showed essentially the same mobilities on 
SDS-PAGE. In general, the placental samples con- 
tained a higher percentage of uncleaved or only 
partially cleaved material - possibly as a result of 
more extensive oxidation of methionine residues. 
The slightly different mobilities of two peptides 
derived from the al-chains is consistent with the 
different mobilities of the uncleaved al (VI)-chains 
noted above. This observation may be explained 
by differences in the pepsin cleavage and/or post- 
translational modifications. 
Indirect immunofluorescence analysis demon- 
strated type VI collagen to be distributed 
throughout the cornea1 stroma (fig.3). Weak stain- 
ing was observed in the Bowman’s layer, whereas 
epithelium and endothelium did not react with the 
antibodies. Consistent with our findings, two re- 
cent reports mentioned the occurrence of type VI 
collagen in mouse cornea based on im- 
munofluorescence [9,17]. These studies also 
described immunoreactivity of the stroma, but not 
of the adjacent basement membranes. In placenta 
and aorta, collagen type VI appeared to be located 
between the cross-striated fibrils of the interstitial 
collagens [9]. How type VI collagen is integrated 
into the tight organisation of the cornea1 ex- 
Fig.3. Indirect immunofluorescence picture of the 
epithelial region of the cornea (bar: 100 pm). EP, 
epithelium; BL, Bowman’s layer; ST, stroma. Inset: 
control. 
tracellular matrix is not yet known and must await 
further investigations. 
To determine the proportion of collagen type VI 
in cornea, we scanned the Coomassie blue-stained 
gels. In both pepsin and SDS extracts, type VI col- 
lagen was the predominant component, compris- 
ing 50-70% of the protein applied to the gels. In 
relation to the original dry weight of the cornea, 
7-10% collagen type VI could be extracted. 
However, this percentage includes only the pepsin- 
resistant domain, which has a molecular mass of 
approx. 150 kDa. The intact type VI molecule with 
its large globular domains has a molecular mass of 
about 400 kDa. This consideration leads to the 
conclusion that the intact type VI collagen must 
comprise as much as one quarter of the cornea1 dry 
weight. Type VI collagen therefore has to be con- 
sidered a major component of the human cornea 
and might play an important role in the organisa- 
tion of its extracellular matrix. 
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